the prognostic impact of circulating plasma cells in patients with multiple myeloma
Published 1 year ago • 457 plays • Length 3:03Download video MP4
Download video MP3
Similar videos
-
1:02
circulating plasma cell levels as a prognostic biomarker in myeloma
-
4:22
prognostic value of mrd and circulating plasma cells in myeloma
-
1:36
the importance of mrd as a prognostic tool in multiple myeloma
-
1:33
circulating tumor cells in multiple myeloma
-
3:05
identifying new therapeutic targets on the surfaceome of myeloma plasma cells with proteomics
-
2:01
ctcs as a biomarker of tumor burden in multiple myeloma
-
3:00
current & emerging biomarkers in multiple myeloma
-
1:05
the prognostic and potentially therapeutic value of liquid biopsy in multiple myeloma
-
5:59
what is hrmm (high-risk multiple myeloma)?
-
6:23
how long will i live with multiple myeloma and is there a cure?
-
6:07
my bone marrow biopsy experience | what is a bone marrow biopsy?
-
1:01
car-t: myeloma toxicities
-
1:11
evaluating the prognostic significance of cpcs in al amyloidosis with next-generation flow cytometry
-
2:46
managing patients with high-risk myeloma
-
2:06
the importance of proteomic analysis in myeloma and future outlooks
-
5:41
ctcs in myeloma: egression mechanisms, transcriptomics, and prognostic value
-
2:35
resistance to immunotherapy in multiple myeloma: mechanisms & monitoring
-
1:47
the role of precursor conditions in myeloma
-
1:09
the efficacy & role of iberdomide in r/r multiple myeloma
-
0:48
myeloma prognosis - the emergence of mrd
-
2:55
covid-19 & multiple myeloma: patient management
-
2:23
multiple myeloma: extramedullary disease